Braveheart Bio, Inc. (BRVE) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of Braveheart Bio, Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BRVE
Braveheart Bio, Inc.
$20.39HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.63HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — BRVE vs RARE
growth of $100 · dividends reinvested · last 1yBRVE +18.6% (+18.6%/yr)RARE -43.8% (-43.8%/yr)BRVE compounded faster over this window
BRVE RARE
Metrics side by side
Total return (annualized)
| Metric | BRVE | RARE |
|---|---|---|
| Total return (1Y) | N/A | -53.37% |
| Total return CAGR (3Y) | N/A | -25.43% |
| Total return CAGR (5Y) | N/A | -30.14% |
| Total return CAGR (10Y) | N/A | -14.91% |
BRVE is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.